Jolanda Schrama

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

Jolien Tol, Miriam Koopman, Annemieke Cats et al. · New England Journal of Medicine · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial

Hanna van Waart, Martijn M. Stuiver, Wim H. van Harten et al. · Journal of Clinical Oncology · 2015 · 657 citations · Full text

Medicine, Health Behavior, Oncology +17

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

Ian F. Faneyte, Jolanda Schrama, J.L. Peterse et al. · British Journal of Cancer · 2003 · 316 citations · Full text

Medicine, Oncology, Pharmacology +15

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

J. Tol, Miriam Koopman, C. J. Rodenburg et al. · Annals of Oncology · 2008 · 215 citations

Medicine, Oncology, Pharmacology +17

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Marieke A. Vollebergh, Esther H. Lips, Petra M. Nederlof et al. · Annals of Oncology · 2010 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +15